This live session took place on February 7th, 2019

During 2018, PBMs began ramping up efforts to address drug spending through Copay Accumulator programs, which prevent manufacturer copay assistance amounts from being applied to a patient’s deductible or out-of-pocket maximum. In many therapy areas, patients rely on copay assistance programs (like drug coupons) that substantially reduce copayments and make therapy adherence easier. Copay Accumulators (and their close relative Copay Maximizers) are the latest move by insurers and pharmacy benefit managers to control drug expenditures at the expense of pharma and patients.
The impact of Copay Accumulator programs to pharma and patients will depend on a variety of factors, including drug costs, deductible levels, patient reliance on copay assistance programs, disease prevalence, drug substitutability, patient income, and the specific details and restrictions of copay assistance programs.
In this webinar, we will discuss trends related to copay accumulator and copay maximizer adoption, potential impacts of copay accumulator programs on high profile therapeutic areas and brands, and potential mitigation strategies for pharma.

  • Valerie Pillo (Host), Market Analyst with Market Access
  • Tyler Dinwiddie, Senior Market Analyst with Market Access

Introducing: Copay Accumulator Threat Assessor

Real world claims data, lives information and market research has come together to provide the most comprehensive copay accumulator database available in an easy to use dashboard. Get deep analysis on copay benefit design, understand business impact and gain informed, actionable insights.

Learn More

How the pandemic has impacted the Federal Health Insurance Exchange in the U.S.

View Now